EFFICACY AND SAFETY OF IRON (III)–HYDROXIDE SUCROSE COMPLEX IN CORRECTION OF ANEMIA STAGE 5D CHRONIC KIDNEYDISEASE HEMODIALYSIS PATIENTS NOT TREATED BY ERYTHROPOIESIS–STIMULATING AGENTS (PROSPECTIVEANALYSIS)

• DOI: 10.31450/ukrjnd.4(44).2014.07
• Publication Date: 2018-06-01T07:38:57Z
• Authors: І. О. Dudar; I. I. Gonchar; І. М. Shifris; Е. К. Krasjuk; V. М. Savchuk; О. М. Loboda; F. О. Pruskiy; V. F. Krot; Т. М. Nechiporuk; N. G. Alekseeva
• Keywords: Transferrin saturation; Iron sucrose

The aim of study was to evaluat the efficacy and safety ofSUFER® (iron (III) sucrose complex) in correction anemia stage 5D chronic kidney disease hemodialysis patients.
 Methods. This included thirty patients undergoing regular (mean age 48,81±3,24 years, mean duration dialysis 30,43±9,25 months) with renal iron deficiency. All were treated SUFER® intravenously 200 mg three times a week. Correction dose determined according manufacturer’s recommendations.
 Results. Mean level offerritin significantly increased from 125,15 ± 21,46 ng / ml 375,56 64,12 (p <0,001), transferrin saturation – 17,48 2,71% 38,21 4,90 <0,001). 23 (76.67%) achieved target levels transferrin, 12 (40% ) adverse events.
 Conclusions. is effective drug patients.